[EN] THIAZOLYL-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES [FR] COMPOSÉS TÉTRACYCLIQUES SUBSTITUÉS PAR THIAZOLYLE ET LEURS PROCÉDÉS D'UTILISATION POUR LE TRAITEMENT DE MALADIES VIRALES
[EN] THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES [FR] COMPOSÉS TÉTRACYCLIQUES À SUBSTITUTION THIOPHÈNE ET LEURS MÉHODES D'UTILISATION POUR LE TRAITEMENT DE MALADIES VIRALES
[EN] HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES<br/>[FR] COMPOSÉS TÉTRACYCLIQUES SUBSTITUÉS PAR UN HÉTÉROCYCLE ET PROCÉDÉS POUR LES UTILISER POUR LE TRAITEMENT DE MALADIES VIRALES
申请人:MERCK SHARP & DOHME
公开号:WO2014110705A9
公开(公告)日:2015-03-05
Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions
We describe the discovery of MK-6169, a potent and pan-genotype hepatitis C virus NS5A inhibitor with optimized activity against common resistance-associated substitutions. SAR studies around the combination of changes to both the valine and aminal carbon region of elbasvir led to the discovery of a series of compounds with substantially improved potency against common resistance-associated substitutions in the major genotypes, as well as good pharmacokinetics in both rat and dog. Through further optimization of key leads from this effort, MK-6169 (21) was discovered as a preclinical candidate for further development.